Safety Study of XT-150 in Participants With ALS
Starting soon · Phase 1
Conditions studied: Amyotrophic Lateral Sclerosis (ALS)
In brief
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150
Key facts
- Study ID
- NCT06704347
- Run by
- Xalud Therapeutics, Inc.
- People needed
- 8
- Starts
- 2027-03-01
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Barrow Neurological Institute (St. Joseph's) — Phoenix, Arizona, United States
- Johns Hopkins University — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Henry Ford Health — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.